Tesamorelin vs Ipamorelin: GHRH Analog vs GHRP for IGF-1 and Visceral Fat
Tesamorelin and ipamorelin both raise growth hormone, but they do it through entirely different receptors and produce very different clinical signatures. The two compounds end up in the same conversation because anyone reading the growth-hormone secretagogue literature for the first time runs into both names within an hour, and the protocol forums tend to use them interchangeably as if "GH peptide" was a single category. They are not. Picking one over the other — or running them in sequence — depends on what you actually want the cycle to do and on which markers you intend to track. This is a practical walk-through of the mechanism difference, the published clinical signals, and the log structure that keeps the two compounds distinguishable.
The mechanism split: GHRH analog vs GHRP
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on the anterior pituitary somatotrophs and amplifies the pulse that the hypothalamus would have produced on its own. The pulses retain their natural cadence, but they are larger, and the result is a sustained elevation in serum IGF-1 once the daily dose has been running for a few weeks. Because the underlying pulse architecture is preserved, the negative feedback loops that prevent runaway GH secretion remain intact.
Ipamorelin is a growth-hormone-releasing peptide (GHRP). It binds a completely different receptor — the ghrelin receptor, also called GHS-R1a — and triggers GH release through a parallel pathway. It does not amplify the GHRH pulse; it superimposes a separate pulse driven by the ghrelin axis. Ipamorelin is the cleanest of the common GHRPs in the sense that it is highly selective for the GH-release function of GHS-R1a, with minimal effect on cortisol or prolactin at clinically relevant doses. The pulses it produces are short and saw-toothed compared to the longer, smoother elevation a GHRH analog produces.
The practical translation: tesamorelin acts on the natural pulse generator, ipamorelin acts on a parallel one. They can be stacked because they hit different receptors, and the combined effect is larger than either alone — this is the standard logic for pairing ipamorelin with a GHRH analog like CJC-1295, covered in the ipamorelin and CJC-1295 stack post. Tesamorelin is essentially a more pharmacologically optimized GHRH option than CJC-1295, with a different stability profile and a much larger clinical evidence base.
What the tesamorelin clinical data actually shows
Tesamorelin is the only compound in this comparison with a Phase III clinical program and an FDA-approved indication. It was approved for the reduction of excess abdominal fat in HIV-associated lipodystrophy in 2010, and the trials that supported that approval are the cleanest visceral-fat data set available for any GH-axis peptide. The headline number from the pivotal studies is roughly a fifteen percent reduction in visceral adipose tissue on CT or MRI over twenty-six weeks at 2 mg daily, with IGF-1 rising into the upper end of the age-adjusted reference range but rarely above it. Subcutaneous fat changes were modest. The visceral-specific effect is the part that is unusual: most weight-loss interventions reduce both depots in proportion, while tesamorelin shifts the ratio.
The mechanism for that depot specificity is not fully settled, but the working explanation is that visceral adipocytes are unusually GH-sensitive and that the sustained IGF-1 elevation produced by daily GHRH analog dosing preferentially drives lipolysis in that compartment. Off-label use in non-HIV populations carries that mechanism forward as a hypothesis, but the head-to-head trial data in healthy or metabolically-syndrome populations is much thinner.
What the ipamorelin clinical data actually shows
Ipamorelin's clinical evidence base is narrower. The compound was developed in the late 1990s as a candidate for GH-deficiency replacement and post-operative ileus, and a handful of Phase I and Phase II studies exist for those indications. None of them were the body-composition trials the protocol forums would want. The strongest claims that can be made from the published work are that ipamorelin raises GH acutely in a dose-dependent way, that the GH pulses produced are largely free of cortisol or prolactin elevation at typical doses, and that the compound is well tolerated over short-term dosing.
What ipamorelin does not have is a clean visceral-fat dataset. The body-composition claims attached to it in protocol-forum writing are extrapolated from the broader GH-secretagogue literature and from the IGF-1 elevations seen when ipamorelin is paired with a GHRH analog. The compound on its own, run at the typical 200–300 mcg subcutaneously two or three times per day, produces modest steady-state IGF-1 changes — meaningfully smaller than tesamorelin monotherapy at the approved dose.
How the cycle structure differs in practice
Tesamorelin is dosed once daily, in the evening, subcutaneously. The 2 mg dose is the studied one; cycles in clinical use ran for twenty-six to fifty-two weeks. The cycle is long because the visceral-fat endpoint is slow.
Ipamorelin is dosed two to three times per day to take advantage of its short half-life and the pulsatile GH-release pattern it produces. The standard timing pattern is pre-bed, with optional fasted-state morning and post-training doses. Cycles in the forum literature run shorter — typically eight to twelve weeks — with breaks intended to limit any receptor desensitization, though the desensitization concern at the GHS-R1a is weaker than at the GHRH receptor.
The cadence difference matters for the stacking arithmetic: a once-daily long-action GHRH peptide and a thrice-daily short-action GHRP are not running on the same clock, and the log needs to keep them on separate tracks.
What to log to keep the two compounds distinguishable
If the cycle is doing more than one thing at once, the log has to do more than one thing too:
- IGF-1 baseline and on-cycle checks. Pre-cycle fasting IGF-1, plus an on-cycle check at weeks four and twelve. Tesamorelin pushes IGF-1 hard; ipamorelin monotherapy pushes it gently. The baseline-to-cycle delta is the cleanest comparator between the two compounds.
- Waist circumference, weekly. Cheaper than a CT scan and informative enough for a body-composition cycle. Same time of day, same tape position, fasted.
- Glucose markers. GH elevation can shift fasting glucose and HOMA-IR upward. Tesamorelin trials saw small but measurable changes in glucose homeostasis. The baseline-and-recheck approach used for IGF-1 applies here too.
- Injection time of day. Tesamorelin is evening; ipamorelin is split across the day. Logging the actual injection time rather than just "daily" matters when the cycle is being read against sleep quality or fasted-state markers.
- Stack annotation. If both are running, log them on separate rows with separate doses. The ipamorelin peptide page and the CJC-1295 page cover the underlying pharmacology in more depth than this post.
What the data does not say
The honest gaps:
- There is no published head-to-head trial of tesamorelin versus ipamorelin on any body-composition endpoint. The comparison here is built from separate studies in separate populations.
- Tesamorelin off-label use in non-HIV populations is supported by mechanism, not by Phase III evidence. Effect sizes outside the studied population are uncertain.
- Long-term GH-axis stimulation has theoretical concerns around IGF-1-mediated cancer risk that the trial duration was too short to fully address. This is a research gap rather than a finding either way.
None of this is medical advice. It is a description of how the two compounds differ in mechanism and what the clinical literature actually supports.
The practical summary
Tesamorelin and ipamorelin live in the same conversation but on different receptors. Tesamorelin is a GHRH analog with a Phase III dataset on visceral fat reduction in HIV lipodystrophy and a much larger evidence base for IGF-1 elevation than any GHRP has. Ipamorelin is a clean, selective GHRP with thinner clinical data on body composition but a useful role as a pulsatile-pulse component in a stacked GH-axis cycle. The two are not interchangeable, and a log that calls them both "GH peptide" loses the structural information that makes the cycle interpretable. Track IGF-1, track waist circumference, track injection time, and the comparison stops being a forum argument and becomes a measurement.